通过依维莫司扩大肝移植免疫抑制最小化 (ELIMINATE)
通过依维莫司扩大肝移植免疫抑制最小化 (CTOT-43)
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
研究概览
地位
条件
详细说明
This study is a multicenter 2:1 randomized nonblinded phase II interventional clinical trial in liver transplant recipients. The primary objective is to determine the safety, efficacy, and tolerability of tacrolimus minimization and eventual withdrawal in conjunction with everolimus monotherapy to preserve renal function. Study subjects will undergo first reduction of tacrolimus with the addition of everolimus. If everolimus is tolerated, subjects will be randomized 2:1 into one of two interventional arms. The first interventional arm will undergo a stepwise reduction of tacrolimus and be on everolimus monotherapy for the remainder of the study. The second interventional arm will remain on the initial reduced tacrolimus dose and everolimus. If subjects prior to randomization are unable to tolerate everolimus, these subjects will be placed in the observational group. These subjects will stop taking everolimus and resume their immunosuppression therapy prior to study enrollment.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Tracia Debnam, MS
- 电话号码:301-761-7414
- 邮箱:Tracia.debnam@nih.gov
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic Hospital Arizona (Site #: 71144)
-
首席研究员:
- Hugo Vargas, MD
-
-
California
-
Los Angeles、California、美国、90095
- 尚未招聘
- Ronald Regan at UCLA Medical Center (Site #: 71123)
-
首席研究员:
- Sammy Saab, MD
-
San Diego、California、美国、92121
- 招聘中
- University of California, San Diego (Site #: 71179)
-
首席研究员:
- Pranab Barman, MD
-
San Francisco、California、美国、94143
- 招聘中
- University of California, San Francisco (Site #: 71108)
-
首席研究员:
- Sandy Feng, MD
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University (Site #: 71110)
-
首席研究员:
- Justin Boike, MD
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan (Site #: 71154)
-
首席研究员:
- Sasha Shingina, MD
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Icahn School of Medicine at Mount Sinai (Site #: 71115)
-
首席研究员:
- Thomas Schiano, MD
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center (Site #: 71139)
-
首席研究员:
- Matthew Kappus, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- University of Pennsylvania (Site #: 71111)
-
首席研究员:
- Abraham Shaked, MD
-
Pittsburgh、Pennsylvania、美国、15260
- 招聘中
- University of Pittsburgh Medical Center (Site #: 71170)
-
首席研究员:
- Scott Biggins, MD
-
-
Texas
-
Dallas、Texas、美国、75246
- 招聘中
- Baylor Medical Center (Site #: 71153)
-
首席研究员:
- Robert Rahimi, MD
-
Houston、Texas、美国、77030
- 尚未招聘
- Houston Methodist (Site #: 71120)
-
首席研究员:
- Mark Ghobrial, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject and/or legal guardian must be able to understand and provide informed consent
- Adult (age greater than or equal to 18 years of age at time of informed consent) recipient of first liver transplant alone (de novo)
- Estimated glomerular filtration rate >=30 ml/min/1.73m^2 at enrollment using the CKD-EPI 2021 equation
- Treatment with tacrolimus therapy, with or without mycophenolic acid derivatives and/or corticosteroids
- Female subjects of childbearing potential with negative pregnancy test upon study entry
- All subjects of reproductive potential agreeing to use contraception for the duration of the study
- Previous vaccination or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, zoster (if >=19 years old), and 2019-nCoV (COVID-19) as outlined in the DAIT Vaccination Guideline
Exclusion Criteria:
-
Inability or unwillingness of a participant to give written informed consent or comply with study protocol
-
Active unresolved systemic viral, bacterial, fungal, or parasitic infection requiring oral or intravenous anti-infective therapy
-
History of autoimmune liver disease including autoimmune hepatitis, primary sclerosing cholangitis, and/or primary biliary cirrhosis, or other contraindications to drug withdrawal
-
History of non-hepatic autoimmune disease requiring current or future systemic immunosuppressive therapy other than per study protocol
-
History post-transplant of Hepatic Artery Thrombosis or Portal Vein Thrombosis.
-
History of recurrent cirrhosis after liver transplantation.
-
Chronic use of systemic glucocorticoids, biological immunomodulatory therapy, or other immunosuppressive agents other than per study protocol
-
History of hepatitis B or C virus infection with detectable viral PCR at enrollment
-
History of prior organ transplantation (liver or other type)
-
History of >= 2 biopsy-proven acute cellular rejection episodes of any severity, >=1 moderate to severe rejection episode (histologically defined or requiring lymphodepletion therapy), or >= 1 antibody- mediated rejection episode
-
Active treatment with any mTOR-inhibitor agent (everolimus, sirolimus)
-
Contraindication to treatment with everolimus (open wound or wound infection; urine protein: creatinine ratio > 0.5 mg/mg; significant pancytopenia (any of the following: WBC <1.5 K/uL or ANC <1000 cells/uL or actively being treated with GCSF; Hb <8.0; platelet count <50K); serum triglycerides > 1000 mg/dL; other per PI)
-
Abnormal liver function tests on study entry: Total Bilirubin (TB)>1.5 mg/dL and Direct Bilirubin (DB) >1.0 mg/dL, Alkaline Phosphatase (AP) >200 U/L, and Alanine Aminotransaminase (ALT)>60 U/L
-
Pregnant on enrollment or plan to become pregnant during the study period
-
Participation in another clinical trial that would interfere with this study's procedures and intervention:
- Use of investigational biologic or drug (within 8 weeks of study enrollment)
- Additional blood collection that would exceed research blood draw limits
- Any other procedure or intervention, in the investigator's opinion would interfere with this study
-
Received live attenuated vaccine(s) within 2 months of enrollment
-
Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
-
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Interventional Group 1
Participants in this group will slowly reduce their dose of tacrolimus and continue everolimus as their only immunosuppression medication. |
其他名称:
其他名称:
其他名称:
|
|
实验性的:Interventional Group 2
Participants in this group will continue to take reduced Tacrolimus and Everolimus IS regimen. |
其他名称:
其他名称:
- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
其他名称:
|
|
无干预:Observational Group
Participants in this group could not tolerate the addition of everolimus. These participants will not be randomized.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
根据 CKD-EPI 2021 方程估算的肾小球滤过率 (eGFR) 的百分比变化。队列 INT-1 和 INT-2 之间
大体时间:从访视 2 到访视 9(肝移植后 12 个月)
|
从访视 2 到访视 9(肝移植后 12 个月)
|
|
根据当地病理情况,经治疗活检证实急性排斥反应 (tBPAR) 的受试者比例。队列 INT-1 和 INT-2 之间
大体时间:从访视 2 到访视 9(肝移植后 12 个月)
|
从访视 2 到访视 9(肝移植后 12 个月)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
肝移植功能的变化:总胆红素
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
移植肝功能的变化:直接胆红素
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
肝移植功能的变化:丙氨酸转氨酶(ALT)
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
肝移植功能的变化:天冬氨酸转氨酶(AST)
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
肝移植功能的变化:碱性磷酸酶
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
肝功能移植失败的时间定义为重新移植、重新移植本身或因移植失败而死亡
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
全因死亡时间
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
经历严重不良心脏事件 (MACE) 的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
经历感染需要住院治疗的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
患有任何恶性肿瘤的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
使用 CKD-EPI 2021 方程,估计肾小球滤过率 (eGFR) 较基线严重恶化 >40% 的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
发生任何主要免疫抑制治疗并发症的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
出现新发外周水肿的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
出现新发血细胞减少症的受试者比例被视为 WBC <3.0x10^9 /L、Hb <8.0 g/dL 或血小板 <50 x 10^9/L。
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
出现新发口腔/胃肠道溃疡的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
出现与依维莫司治疗相关的新发胃肠道症状(恶心、呕吐、腹痛或腹泻)的受试者比例。
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
出现新发肺炎的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
发生新发肝动脉血栓形成的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
发生其他不良事件的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
发生与依维莫司治疗相关的任何不良事件的受试者比例
大体时间:从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
从第 1 次访视到第 11 次访视(肝移植后 20 个月)
|
|
估计肾小球滤过率(EGFR)的变化百分比百分比
大体时间:从访问1到访问11(肝后移植后20个月)
|
从访问1到访问11(肝后移植后20个月)
|
|
经过活检证明急性排斥反应的受试者百分比(TBPAR)
大体时间:从访问1到访问11(肝后移植后20个月)
|
从访问1到访问11(肝后移植后20个月)
|
合作者和调查者
调查人员
- 首席研究员:Justin Boike, MD、Northwestern University Feinberg School of Medicine: Transplantation
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- DAIT CTOT-43
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD 共享时间框架
24 Months after database lock for the trial
IPD 共享访问标准
Open Access
IPD 共享支持信息类型
- 研究方案
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.